Yu-Feng Li1,2, Yu-Cheng Xiang1,2, Qiu-Qiang Zhang1,2, Wei-Lin Wang1,2,3,4. 1. Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. 2. Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou, China. 3. Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou, China. 4. Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, Hangzhou, China.
Abstract
BACKGROUND: Because the overall prognosis remains dismal for patients with resected pancreatic cancer (PC), we aimed to explore the prognostic impact of examined lymph node (ELN) count on lymph node (LN)-negative pancreatic body/tail ductal adenocarcinoma. METHODS: Patients' data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database (National Cancer Institute, USA) to investigate the relationship between ELN count and survival outcomes of LN-negative pancreatic body/tail ductal adenocarcinoma. RESULTS: A total of 700 patients were included, and the median number of ELNs was 11. The respective 1-, 3-, 5-year overall survival (OS) rates were 75.3%, 37.7%, 30.3%, and the 1-, 3-, 5-year cancer-specific survival (CSS) were 78.3%, 41.7%, 34.5%. The X-tile analysis showed that 14 was the most optimal cutoff for both OS and CSS. Kaplan-Meier survival analysis indicated that patients with ELNs >14 had better OS and CSS than ELNs ≤14. Multivariate Cox analysis showed ELNs ≤14 was an independent risk factor for both OS [hazard ratio (HR), 1.357; 95% confidence interval (CI), 1.080-1.704; P=0.009] and CSS (HR, 1.394; 95% CI, 1.092-1.778; P=0.008). CONCLUSIONS: ELN count is associated with the survival rate in patients with LN-negative pancreatic body/tail ductal adenocarcinoma. Accurate nodal staging for these patients requires more than 14 ELNs. 2020 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: Because the overall prognosis remains dismal for patients with resected pancreatic cancer (PC), we aimed to explore the prognostic impact of examined lymph node (ELN) count on lymph node (LN)-negative pancreatic body/tail ductal adenocarcinoma. METHODS: Patients' data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database (National Cancer Institute, USA) to investigate the relationship between ELN count and survival outcomes of LN-negative pancreatic body/tail ductal adenocarcinoma. RESULTS: A total of 700 patients were included, and the median number of ELNs was 11. The respective 1-, 3-, 5-year overall survival (OS) rates were 75.3%, 37.7%, 30.3%, and the 1-, 3-, 5-year cancer-specific survival (CSS) were 78.3%, 41.7%, 34.5%. The X-tile analysis showed that 14 was the most optimal cutoff for both OS and CSS. Kaplan-Meier survival analysis indicated that patients with ELNs >14 had better OS and CSS than ELNs ≤14. Multivariate Cox analysis showed ELNs ≤14 was an independent risk factor for both OS [hazard ratio (HR), 1.357; 95% confidence interval (CI), 1.080-1.704; P=0.009] and CSS (HR, 1.394; 95% CI, 1.092-1.778; P=0.008). CONCLUSIONS: ELN count is associated with the survival rate in patients with LN-negative pancreatic body/tail ductal adenocarcinoma. Accurate nodal staging for these patients requires more than 14 ELNs. 2020 Journal of Gastrointestinal Oncology. All rights reserved.
Entities:
Keywords:
Lymph nodes (LNs); Surveillance, Epidemiology, and End Results database (SEER database); pancreatic cancer (PC); prognosis
Authors: Rene Warschkow; Bernhard Widmann; Ulrich Beutner; Lukas Marti; Thomas Steffen; Marc Schiesser; Bruno M Schmied Journal: Pancreas Date: 2017 May/Jun Impact factor: 3.327
Authors: Marianne Huebner; Michael Kendrick; Kaye M Reid-Lombardo; Florencia Que; Terry Therneau; Rui Qin; John Donohue; David Nagorney; Michael Farnell; Michael Sarr Journal: J Gastrointest Surg Date: 2012-03-16 Impact factor: 3.452
Authors: Giuseppe Malleo; Laura Maggino; Cristina R Ferrone; Giovanni Marchegiani; Mari Mino-Kenudson; Paola Capelli; Borislav Rusev; Keith D Lillemoe; Claudio Bassi; Carlos Fernàndez-Del Castillo; Roberto Salvia Journal: Ann Surg Date: 2019-12 Impact factor: 12.969
Authors: S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi Journal: Ann Surg Date: 1998-10 Impact factor: 12.969
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Johanna A M G Tol; Dirk J Gouma; Claudio Bassi; Christos Dervenis; Marco Montorsi; Mustapha Adham; Ake Andrén-Sandberg; Horacio J Asbun; Maximilian Bockhorn; Markus W Büchler; Kevin C Conlon; Laureano Fernández-Cruz; Abe Fingerhut; Helmut Friess; Werner Hartwig; Jakob R Izbicki; Keith D Lillemoe; Miroslav N Milicevic; John P Neoptolemos; Shailesh V Shrikhande; Charles M Vollmer; Charles J Yeo; Richard M Charnley Journal: Surgery Date: 2014-07-22 Impact factor: 3.982
Authors: S B Dreyer; N B Jamieson; R Upstill-Goddard; P J Bailey; C J McKay; A V Biankin; D K Chang Journal: Br J Surg Date: 2018-01 Impact factor: 6.939